Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer

Giuseppe Cicero, Rossella De Luca, Francesco Dieli, Rossella De Luca, Giuseppe Cicero

Risultato della ricerca: Articlepeer review

3 Citazioni (Scopus)

Abstract

Background/Aim: A clinical trial demonstrated that treatment with oral multikinase regorafenib improved overall survival (OS), progression-free survival (PFS), and disease control [GarcÃa-Alfonso et al.: J Clin Transl Oncol 2016;18:1072-1081; Bertocchi et al.: J Chemother 2017;29:102-105]. In this study, we aimed to evaluate its effectiveness in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy with docetaxel plus prednisone. Materials and Methods: 60 patients were enrolled. OS has been assessed as the primary endpoint while PFS, quality of life, safety, and response rate represented secondary endpoints. Results: A modest tolerability was observed in our group showing a manageable toxicity profile and a modest objective response rate. It was associated with stable disease. A significant correlation between quality of life and OS was also noticed. Conclusions: Regorafenib has been proven to be an effective and well-tolerated therapeutic option in patients with mCRPC progressing after docetaxel plus prednisone treatment.
Lingua originaleEnglish
Numero di pagine0
RivistaOncology
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer'. Insieme formano una fingerprint unica.

Cita questo